Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228799 | 0.82 | KMT2A (0.57) | KMT2AMAPTMTNR1AMTNR1BPOLB | |
| SCHEMBL628528 | 0.80 | KMT2A (0.70) | KMT2AMTNR1AMTNR1BPOLBSMN1; SMN2 | |
| SCHEMBL3407197 | 0.79 | MCHR1 (0.46) | MAPTMTNR1AMTNR1B | |
| SCHEMBL2673224 | 0.77 | ALDH1A1 (0.46) | KMT2AMAPTPOLBTSHRCYP1A2 | |
| SCHEMBL9451283 | 0.77 | MAPT (0.54) | KMT2AMAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL4015952 | 0.75 | MAPT (0.46) | KMT2AMAPTPOLBSMN1; SMN2HTT | |
| SCHEMBL8935639 | 0.74 | KMT2A (0.62) | KMT2AMTNR1AMTNR1BPOLBSMN1; SMN2 | |
| SCHEMBL4650644 | 0.74 | KMT2A (0.62) | KMT2AMTNR1AMTNR1BPOLBSMN1; SMN2 | |
| SCHEMBL628126 | 0.74 | KMT2A (0.53) | KMT2AMAPTMTNR1AMTNR1BPOLB | |
| SCHEMBL6975828 | 0.74 | XDH (0.42) | KMT2AMAPTSMN1; SMN2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| EP-2331513-A1 | PROCESS FOR PREPARATION OF BOSENTAN | Cadila Healthcare Limited (IN) | 2011-06-15 | — | — | EP | claimed |
| WO-2010032261-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2010-03-25 | — | — | WO | claimed |
| US-20140275535-A1 | ACID ADDITION SALTS OF BOSENTAN | BIOCON LIMITED (IN) | 2014-09-18 | — | — | US | disclosed |
| EP-2768812-A1 | ACID ADDITION SALTS OF BOSENTAN | Biocon Limited (IN) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013057545-A1 | ACID ADDITION SALTS OF BOSENTAN | BIOCON LIMITED (IN) | 2013-04-25 | — | — | WO | disclosed |
| EP-2132199-A1 | SUBSTITUTED PYRIMIDINES | Auspex Pharmaceuticals Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008122020-A1 | SUBSTITUTED PYRIMIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242687-A1 | SUBSTITUTED PYRIMIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| EP-0959072-B1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-0743307-B1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO (JP) | 2001-09-12 | — | — | EP | disclosed |
| EP-0959073-A1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1999-11-24 | — | — | EP | disclosed |
| EP-0959072-A1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1999-11-24 | — | — | EP | disclosed |
| US-5739333-A | 4-SULFONAMIDO-6-ARYLOXY OR -AMINOALKYLENEOXY,-AMINO, OR -THIOPYRIMIDINES; ENDOLTHELIN ANTAGONISTS; HYPOTENSIVE AND ULCER AGENTS; ASTHMA; RAYNAUD DISEASE; CARDIOVASCULAR DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0743307-A1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1996-11-20 | — | — | EP | disclosed |
| US-5273993-A | Antiarthritic agents; osteoporosis | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-12-28 | — | — | US | disclosed |
| US-5194446-A | Antiarthritic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-16 | — | — | US | disclosed |
| US-5025031-A | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants | A. H. ROBINS CO., INC. (US) | 1991-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CYP2D6, CYP3A5, QDPR | KMT2A 3992/4885MAPT 4231/4885MTNR1A 2730/4885 |
| US-20140275535-A1 | ACID ADDITION SALTS OF BOSENTAN | NCLN, EDNRB, EDNRA | KMT2A 4488/4885MAPT 3518/4885MTNR1A 3402/4885 |
| US-20080242687-A1 | SUBSTITUTED PYRIMIDINES | EDNRB, EDNRA, ECE1 | KMT2A 4436/4885MAPT 3990/4885MTNR1A 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.